Global health: Universal health coverage
CEPA’s work supports organisations and governments in moving towards UHC through contributing to the quality, effectiveness, equity, accountability and financial sustainability of health service delivery.
All Member States of the United Nations agreed on the Sustainable Development Goals (SDGs) in New York in 2015, aspiring for a safer, fairer, and healthier world by 2030.[CS1] [LG2] Goal 3.8 of the SDGs aims to “achieve universal health coverage (UHC), including (i) financial risk protection, (ii) access to quality essential health care services and (iii) access to safe, effective, quality and affordable essential medicines and vaccines for all”.
CEPA’s work supports organisations and governments in moving towards UHC through contributing to the quality, effectiveness, equity, accountability and sustainability of development aid in the health sector. Our services to clients include evaluation and impact assessments, strategy and governance, organisational support, health policy and technical advisory and operational research and evidence synthesis.
For example, CEPA has experience in supporting access to quality services through support community engagement, gender and broader social aspects of health. In 2018-19, CEPA was appointed to develop an evaluation framework and methodology to increase the capacity of the Stop TB Partnership to evaluate its community, human rights and gender (CRG) focused work. CEPA also conducted a review of UNFPA’s safe motherhood scheme - an intervention that aimed to address barriers in accessing maternal health services. Our wider experiences have also supported access to affordable essential medicines and vaccines for all, for example through our evaluation of Unitaid’s support for advocacy for affordable HCV treatment in low- and middle-income countries.
In addition, CEPA has engaged in a broad range of work on supporting multi-sectoral partnerships, which are necessary due to the growing complexities of global health. For example, we conducted an evaluation of the Global Fund’s Cooperation Agreements with WHO and the Stop TB Partnership on the provision of technical assistance to support the development of country concept notes and grant-making. The aim of thematic review was to assess the relevance, effectiveness, efficiency, impact and sustainability of the Cooperation Agreements, and to capture lessons learned and develop recommendations to improve technical assistance provision in the future.
Communicable & non-communicable diseases
We have comprehensive knowledge and expertise in communicable diseases, including HIV/AIDS,...
Health & community systems strengthening
Our team has substantial experience in the design, implementation and evaluation of...
Our team has extensive experience in immunisation systems strengthening and knowledge context...
Market dynamics, supply & access
CEPA has substantive experience in retrospective and prospective market dynamics analyses, including...
Sexual, reproductive, maternal, newborn, child & adolescent health
We have a strong understanding of the priorities and issues on the...
Universal health coverage
CEPA’s work supports organisations and governments in moving towards UHC...
Our key contacts for our Global health practice are...
If you would like to talk to someone regarding our experience in this sector please contact our experts.View the Global health team
Global health News & insights
CEPA recognised as one of the UK’s leading management consultants
Following another year of providing high-quality advice to our clients across our core sectors, we are grateful for the positive feedback from the market, which has led to CEPA’s inclusion in the Financial Times’ independent ratings report.
CEPA modelling shows the economic and public health impact of voluntary licensing
Licences negotiated by the Medicines Patent Pool will save the international community an estimated USD 3.5bn and 170k lives by 2030. This is according to a new methodology for estimating the impact of licences that was validated via a peer-reviewed article published in The Lancet.
Junior global health consultant vacancy
We are currently recruiting a junior consultant to join our London team to support our work in global health.
CEPA evaluates Unitaid’s investments in Hepatitis C
Unitaid has invested more than US$45 million since 2015 in support of improving access to care for hepatitis C. We are pleased to have provided them with a portfolio evaluation and end of grant evaluations.
Senior global health consultant sought
We are currently recruiting a senior level global health consultant with a minimum of 10 years’ relevant work experience to contribute to leadership of the Global Health team in London.
Applying the ‘no-one worse off’ criterion
Laura Grobicki has contributed to an article published in the journal 'AIDS', related to the HIV allocative efficiency modelling work she undertook in Togo.
Evaluation of cooperation agreements between health organisations
The Global Fund commissioned CEPA to conduct an evaluation of its Cooperation Agreements with WHO and the Stop TB Partnership on the provision of technical assistance to support the development of country concept notes and grant-making.
Thematic review to assess an approach to investing in resilient & sustainable systems for health
CEPA conducted a thematic review to assess the Global Fund’s current approach to investments in Resilient and Sustainable Systems for Health (RSSH).
Evaluation of community, human rights and gender interventions
CEPA was appointed to develop an evaluation framework and methodology to help the Stop TB Partnership to evaluate its community, human rights and gender focused work.
Monitoring of Gavi Market Shaping Externalities
As part of its Supply and Procurement Strategy for 2016-2020, Gavi committed to monitor any negative and positive unintended consequences, so-called externalities, that could arise from its market shaping activity.
Evaluation of Gavi health system strengthening support to Nepal
Gavi commissioned an evaluation of its Health System Strengthening (HSS) support to Nepal through the pooled funding mechanism.
Modelling ROI on reproductive, maternal, newborn, child & adolescent health & nutrition interventions
CEPA conducted a modelling of the Global Financing Facility’s return on investment for Reproductive, Maternal, Newborn, Child and Adolescent Health and Nutrition (RMNCAH-N) interventions.
Making markets for children with HIV
Our evaluation of the impact of Unitaid's support for treating children living with HIV demonstrated the pivotal role the organisation had in creating a market for paediatric antiretroviral (ARV) medicine.
Framework for integration of disease programmes into health systems
CEPA was commissioned by the Global Fund to develop a framework and diagnostic tool for assessing governance-level bottlenecks to the integration of disease programmes into national health systems.
Mid-term evaluation of the Unitaid “Self-testing Africa (STAR)” project
CEPA was appointed to review the implementation of the first phase of Unitaid’s HIV self-testing grant to identify areas that worked well and those that worked less well, determine the extent to which the project achieved its intended impacts.
Advisory support to the Partnership for Maternal, Newborn and Child Health
CEPA was asked to carry out an analysis of the factors affecting provision of Overseas Development Assistance (ODA) for Sexual, Reproductive, Maternal, Newborn, Child and Adolescent related health programmes (SRMNCAH).
Review of the Global Task Force on Cholera Control
CEPA was appointed by the Global Task Force on Cholera Control (GTFCC) to conduct an independent review of the revitalised Task Force.
Evaluation of the ‘Improving Severe Malaria Outcomes’ project
CEPA was appointed to conduct a mid-term and an end-term review of Unitaid’s “Improving Severe Malaria Outcomes” project.
Development of Global Strategy for Womens’, Childrens’ & Adolescents’ Health
CEPA supported the PMNCH’s Consultation on the Global Financing Facility in conducting a global consultation process and producing a report.
Learning agenda – Gavi’s new country engagement framework
CEPA was appointed by Gavi to capture feedback and document lessons during the early implementation phase of Gavi’s new country engagement framework approach.
Development of Gavi application guidelines
CEPA was commissioned to develop Gavi’s Application Guidelines and Forms for 2016 and 2017.
Meta-review of Gavi health systems strengthening (HSS) country evaluations
CEPA conducted a meta-review of 14 country evaluations of Gavi HSS support in order to inform Gavi’s review of its HSS window of support.
Prospective evaluation design for the Bangladesh Home Fortification Project
CEPA supported CIF with an evaluation of the Bangladesh Home Fortification Project, aimed at reducing anaemia among young children.
Evaluation of the Stop TB Partnership
CEPA was appointed to undertake a Value for Money (VfM) evaluation of the Stop TB Partnership covering the period 2007 to 2013.
Innovative financing mechanisms for malaria elimination
CEPA was appointed to review current financing trends for malaria eliminating countries and consider suitable innovative financing mechanisms that could be developed to support malaria elimination.
Review of Unitaid’s Medicines Patent Pool (MPP)
CEPA undertook a review to closely assess the strategic direction, positioning and operations of the MPP.
Evaluation of the Norway India Partnership Initiative
CEPA was appointed by the Evaluation Department at Norad to conduct a process evaluation of the Norway India Partnership Initiative (NIPI) with the aim to reduce child and maternal mortality.
Investment case for Civil Registration and Vital Statistics
The purpose of the assignment was to prepare an investment case for Civil Registration and Vital Statistics (CRVS) systems, to serve as a key advocacy document to garner support for and investment in, CRVS systems.
Mid-term review of GAIN’s Infant and Young Child Nutrition programme
CEPA conducted a mid-term review of GAIN’s Infant and Young Child Nutrition programme.
Evaluation of Gavi Phase II
A consortium led by CEPA carried out the second evaluation of Gavi. The evaluation assessed Gavi’s performance since inception, focusing on the period between 2006 and 2009.
Market Dynamics Study on drugs and diagnostics for communicable diseases
CEPA was commissioned by the Global Fund to conduct a Market Dynamics Study focusing on seven product areas (drugs and diagnostics for the three disease areas, and Long-Lasting Insecticide-treated Nets).